Clinical trials: Resectable Esophageal Cancer
Esophageal Squamous Cell Carcinoma
Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
Abstract Objective: This study aims to investigate the potential clinical impact of neoadjuvant immunotherapy in resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT06388135
- Testing
- Serplulimab Combined With Nab-paclitaxel and Cisplatin, nab-paclitaxel，Cisplatin
- Volunteers
- 80 people
- Sponsor
- Yang Jianjun, PhD
Esophageal Squamous Cell Carcinoma
Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC
Esophageal cancer, the 7th most common cancer globally, accounts for more than half a million deaths each year. The incidence of ESCC, the most common histologic type, has been stable, whereas the incidences of esophageal and…
- Trial name
- NCT05213312
- Testing
- Nivolumab, Cisplatin, Paclitaxel
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
The purpose of this study was to evaluate the safety, feasibility and outcome of anti-PD-1 antibody (Tislelizumab, BeiGene) combined with neoadjuvant chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by minimally…
- Trial name
- iCROSS (NCT04973306)
- Testing
- Neoadjuvant Chemoradiotherapy, Tislelizumab, Ivor-Lewis or Mckeown Esophagectomy(Mckeown Esophagectomy recommended)
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Cancer
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
We intend to conduct a prospective single-arm clinical study to explore the efficacy and safety of immunochemotherapy in neoadjuvant therapy in elderly patients with advanced esophageal squamous cell carcinoma.
- Trial name
- NCT06403878
- Testing
- Carboplatin, Nab paclitaxel, Sintilimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sichuan University
Esophageal Cancer, Gastric Adenocarcinoma
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
The purpose of this study to find out whether adding trastuzumab and pembrolizumab to standard chemotherapy is an effective treatment for resectable HER2+ esophagogastric cancer.
- Conditions
- Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation
- Trial name
- NCT06123338
- Testing
- Pembrolizumab, Trastuzumab, Oxaliplatin
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Carcinoma
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
We plan to conduct a single-center,prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced…
- Trial name
- NCT07312578
- Testing
- Nimotuzumab, camrelizumab, Albumin paclitaxel
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Peking University
Esophagus Cancer
Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label…
- Trial name
- CELAEC (NCT02972372)
- Testing
- CRT, surgery
- Where
- 2 sites in China
- Volunteers
- 196 people
- Sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
Esophageal Cancer (EsC)
A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma
This study is a prospective, observational clinical study. In this study, 30 patients with resectable locally advanced esophageal squamous carcinoma will be prospectively enrolled and treated with adebrelimab (SHR-1316) combined…
- Trial name
- NCT06869213
- Testing
- Adebrelimab (SHR-1316) + Nab-paclitaxel + Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University Cancer Hospital & Institute
Esophageal Cancer
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
The primary aim of the PERSuaDER-trial is to evaluate the effect of SDD on infectious complications after esophagectomy, focussed on the prevention of pneumonia
- Trial name
- PERSuaDER (NCT05865743)
- Testing
- SDD
- Where
- 2 sites in Belgium, Netherlands
- Volunteers
- 854 people
- Sponsor
- Radboud University Medical Center
Resectable Esophageal Cancer
Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection
This research study is evaluating a new type of esophagus cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for esophagus cancer patients who have completed adjuvant therapy following…
- Trial name
- NCT05307835
- Testing
- iNeo-Vac-P01, GM-CSF
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Cancer, Gastric Cancer
Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma
This study is being done to find out how effective a new treatment strategy is on your cancer. In this strategy, the response your tumor has to the first cycle of therapy will help select the next treatments.
- Trial name
- NCT00737438
- Testing
- epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of esophageal squamous cell carcinoma patients was not significantly decreased.
- Trial name
- NCT07244978
- Testing
- Ivonescimab（AK112), Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy, Esophagectomy, Sample
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Esophageal Neoplasms, Gastro-esophageal Junction Cancer
PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
Resectable esophageal or junctional cancer requires medical treatment by radiotherapy and chemotherapy followed by surgery. Currently, one of the most commonly used chemotherapy treatment is the FOLFOX.
- Trial name
- PROTECT (NCT02359968)
- Testing
- FOLFOX, CarboP-pacliT
- Where
- 10 sites in France
- Volunteers
- 106 people
- Sponsor
- Centre Oscar Lambret
Esophageal Cancer
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
This is a study for patients with resectable, locally advanced esophageal cancer. There is evidence to suggest that celecoxib in combination with cisplatin and irinotecan (CPT-11) may work well with radiation therapy to kill…
- Trial name
- NCT00137852
- Testing
- Cisplatin, Irinotecan, Celecoxib
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dana-Farber Cancer Institute
Esophageal Cancer
Gefitinib, Cisplatin, Irinotecan, and Radiation Therapy Before Surgery in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and irinotecan, work in different ways to stop the growth of tumor…
- Trial name
- NCT00290719
- Testing
- cisplatin, gefitinib, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Esophagus Cancer
Proton Therapy for Esophageal Cancer
The goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin /paclitaxel, with conformal proton modality, followed by definitive…
- Trial name
- NCT01684904
- Testing
- Proton radiation
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Loma Linda University
Adjuvant Radiotherapy
Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma in the Era of Immunotherapy
This study is a multicenter, prospective, randomized phase II trial aimed at exploring the value of adjuvant radiotherapy in patients at high risk of recurrence after neoadjuvant chemoradiotherapy for esophageal cancer.
- Trial name
- NCT06272214
- Testing
- Adjuvant radiotherapy, Observation
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Zhejiang Cancer Hospital
Radiotherapy Side Effect, Chemotherapy Effect
Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）
To provide comprehensive efficacy and safety profiles of neoadjuvant chemoradiotherapy (NCRT) versus neoadjuvant chemotherapy (NCT) versus surgery alone in resectable oesophageal carcinoma.
- Conditions
- Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma, Effect of Drugs
- Trial name
- NCT04027543
- Testing
- Neoadjuvant chemoradiotherapy, Oesophagectomy, Neoadjuvant chemotherapy
- Where
- 3 sites in United States, China
- Volunteers
- 423 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Gastro Esophageal Junction Cancer, Stomach Cancer
Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma
To evaluate the antitumor activity and safety/tolerability of the combination (mFOLFOX + Pembrolizumab) in patients with potentially resectable adenocarcinoma of the Gastroesophageal Junction (GEJ) and stomach.
- Conditions
- Gastro Esophageal Junction Cancer, Stomach Cancer, Adenocarcinoma
- Trial name
- NCT03488667
- Testing
- Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab, Adjuvant Treatment - mFOLFOX & Pembrolizumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Kansas Medical Center
Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
In the management of locally advanced esophageal squamous cell carcinoma, the outcomes associated with surgical resection, whether conducted alone or supplemented with postoperative adjuvant radiotherapy and chemotherapy, have…
- Trial name
- NCT07505186
- Testing
- Camrelizumab, Esophagectomy, Sample
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine